

Chagas disease - Pipeline Insight, 2021

<https://marketpublishers.com/r/C748F14D6DFFEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C748F14D6DFFEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Chagas disease – Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chagas disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chagas disease Understanding

Chagas disease: Overview

Chagas disease, also known as American trypanosomiasis, is a potentially life-threatening illness caused by the protozoan parasite *Trypanosoma cruzi*. About 6 million to 7 million people worldwide are estimated to be infected with *T. cruzi*, the parasite that causes Chagas disease. The disease is found mainly in endemic areas of 21 continental Latin American countries, where it is mostly transmitted to humans and other mammals by contact with faeces or urine of triatomine bugs (vector-borne), known as 'kissing bugs', among many other popular names, depending on the geographical area. Chagas disease presents itself in two phases. The initial acute phase lasts for about two months after infection. During the acute phase, a high number of parasites circulate in the blood but in most cases, symptoms are absent or mild and unspecific.

During the chronic phase, the parasites are hidden mainly in the heart and digestive muscle. Up to 30% of patients suffer from cardiac disorders and up to 10% suffer from digestive (typically enlargement of the oesophagus or colon), neurological or mixed alterations. Chagas disease can be treated with benznidazole and also nifurtimox.

'Chagas disease - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chagas disease pipeline landscape is provided which includes the disease overview and Chagas disease treatment guidelines. The assessment part of the report embraces, in depth Chagas disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chagas disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chagas disease R&D. The therapies under development are focused on novel approaches to treat/improve Chagas disease.

Chagas disease Emerging Drugs Chapters

This segment of the Chagas disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chagas disease Emerging Drugs

Fosravuconazole: Seren Pharmaceuticals

Fosravuconazole is a tri-azole antifungal agent discovered by Eisai. The company Executed License Agreement with Eisai Co., Ltd. of Ravuconazole (BFE1224)

(Fosravuconazole) for antifungal agent in the territory of Japan excluding Chagas' disease. The drug is in Phase II stage of development for the treatment of patients with Chagas disease.

Further product details are provided in the report

Chagas disease: Therapeutic Assessment

This segment of the report provides insights about the different Chagas disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chagas disease

There are approx. 4+ key companies which are developing the therapies for Chagas disease. The companies which have their Chagas disease drug candidates in the most advanced stage, i.e. Phase II include, Seren Pharmaceuticals.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Chagas disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various

ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chagas disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chagas disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chagas disease drugs.

Chagas disease Report Insights

Chagas disease Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Chagas disease Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Chagas disease drugs?

How many Chagas disease drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for

the treatment of Chagas disease?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chagas disease therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Chagas disease and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Chagas disease: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Chagas disease – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Chagas disease companies' collaborations, Licensing, Acquisition -Deal Value Trends

Chagas disease Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

Fosravuconazole: Seren Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Preclinical stage products

Comparative Analysis

Chagas disease vaccine: ConserV Bioscience

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Chagas disease Key Companies

Chagas disease Key Products

Chagas disease- Unmet Needs

Chagas disease- Market Drivers and Barriers

Chagas disease- Future Perspectives and Conclusion

Chagas disease Analyst Views

Chagas disease Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Chagas disease

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Chagas disease

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Chagas disease - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C748F14D6DFFEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C748F14D6DFFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970